Medicamen Organics Limited
Incorporated in 1995, Medicamen Organics Limited develops pharmaceutical dosages including generic doses in the form of tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders.
What Medicamen files
- Others49
- Important35
- Board Meeting12
- Updates12
- Investor Meet7
- Insider Trade2
Medicamen Organics Limited has informed the Exchange regarding the Outcome of the Management Committee Meeting held on June 09, 2026.
Medicamen Organics (MEDIORG), listed on the SME platform, is exempt from submitting the Annual Secretarial Compliance Report for the financial year ended March 31, 2026. This simplifies reporting obligations due to its SME status.
Medicamen Organics' Board approved an amended Code for Fair Disclosure of Unpublished Price Sensitive Information. This update enhances transparency and strengthens internal controls around price-sensitive data, aiming to prevent misuse.
Company is undertaking a preferential issue to raise INR 13.65 Cr. This includes INR 2.50 Cr via promoter loan conversion, reducing their outstanding loan to INR 3.15 Cr. Funds will be utilized for business requirements and working capital.
Medicamen Organics now provides access to a valuation report on its website. This report pertains to significant corporate matters previously put to shareholders for approval at an EGM, aiding investor understanding of transactions requiring fair value.